Interaction between PPARA genotype and β-blocker treatment influences clinical outcomes following acute coronary syndromes
Philip G. Jones(University of Missouri–Kansas City), Adam Garsa(Washington University in St. Louis), Sharon Marsh(Washington University in St. Louis), Carmen C. Sucharov(University of Colorado Denver), John A. Spertus(Saint Luke's Health System), Daniel P. Kelly(Cardiovascular Institute of the South), David E. Lanfear(Henry Ford Health System), Carla J. Weinheimer(University of Washington), Sharon Cresci(Washington University in St. Louis), Jun Wu(Chinese Academy of Sciences), Michael Courtois(Washington University in St. Louis), Howard L. McLeod(University of North Carolina at Chapel Hill), Michael A. Province
Cited by 0
Related Papers
The p53-mdm-2 autoregulatory feedback loop.
|Genes & Development|1993|1.8k
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update
|Circulation|2011|1.8k
Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and Regulation of Inflammation
|Cell Metabolism|2016|1.5k
Peroxisome proliferator–activated receptor γ coactivator-1 promotes cardiac mitochondrial biogenesis
|Journal of Clinical Investigation|2000|1.3k
Medical Therapy for Heart Failure With Reduced Ejection Fraction
|Journal of the American College of Cardiology|2018|1.3k